Bone Turnover/CKD-BMD ChLIA Products

Disease information

Throughout life, old bone is constantly removed (bone resorption) and replaced by new bone (formation). This continual process, named bone remodeling, is essential for the maintenance of healthy bone mass and structural integrity1.

Bone turnover markers (BTMs) are released during the bone remodeling process and are measurable in blood or urine. Bone markers may be classified as bone formation markers bone alkaline phosphatase (BAP) or resorption markers such as the C-terminal telopeptides of type I collagen (CTX-I)

Parathyroid hormone is an important regulator of cell activity and calcium metabolism.

Diagnostic Guidelines

BTMs are increasingly used in routine clinical management of osteoporosis, especially for monitoring therapy, in addition to their use in other metabolic bone disease, such as Paget’s disease of bone and osteomalacia:

CTX-I has been designated as a reference BTM for use in the management of osteoporosis^1-3.
Concentrations of bone turnover enzymes in blood provide reliable information of bone turnover in patients with impaired kidney function:
- BAP and TRACP5b are recommended for use in the assessment of bone disease in patient with CKD-MBD4 ⁵.

Hyperparathyroidism (HPT) is characterised by an increased PTH level in the blood. Secondary complications of HPT include decreased bone density, osteoporosis and kidney stones.

In hypoparathyroidism, the PTH concentration is too low. It is often caused by thyroid surgery in which the parathyroid is also removed – sometimes unintentionally. The resulting calcium deficiency can lead to severe muscle cramps and even cardiac insufficiency.

Bone Turnover Products

For In Vitro Diagnostic Use

wdt_ID	Method	Parameter	Sample	Part Number	Control	Calibrator
638	ChLIA	Beta Crosslaps® CTX-1)	Serum, plasma	IS-3000N	IS-3030N	IS-3020N
639	ChLIA	Ostase® BAP	Serum, plasma	IS-2800US	IS-2830US	Included
640	ChLIA	Intact Parathyroid hormone (PTH)	Serum, plasma	IS-2200	IS-3230	IS-3235

References

1. www.iofbonehealth.org
2. Vasikaran S et al. Clin Chem Lab Med 2011 Aug; 49(8):1271–1274.
3. Bauer D et al. Osteoporos Int. 2012 Oct;23(10):2425-33
4. Ketteler M et al. Ann Intern Med. 2018 Mar 20;168(6):422-430.
5. Bhattoa, H.P. et al. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int 36, 579–608 (2025)

Bone Turnover/CKD-BMD ChLIA

Disease information

Bone Turnover Products

Contact our Antigen Product Team for further details and information

Get in touch

Quick Links

Subscribe